SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

June 29, 2015 08:00 ET

Sirona Biochem Announces SGLT2 Inhibitor and Skin Lightening Patent Granted

VANCOUVER, BC--(Marketwired - June 29, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its patent entitled "Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars" has been granted by the African Regional Intellectual Property Organization (composed of 19 African countries) and the patent office of South Africa. It is in the process of being granted by the European Patent Office and the patent office of Singapore. The process is proceeding without any known obstacles in the final regions. The patent is one of seven owned by Sirona's subsidiary, TFChem, and covers the SGLT2 Inhibitor as well as the skin lightening technology specific to TFC-849.

"Our patents are what protect our inventions and intellectual property. They are key assets of the company and we are thrilled with the ease we've had in the review and granting processes," said Dr. Howard Verrico, CEO. "We are confident we'll have the same success for this patent family in other countries, such as: China, USA, Canada, Mexico, Brazil, Australia, India and Japan and we'll continue to grow our IP portfolio with technology advancements."

Diabetes is a global epidemic. The market size for Type 2 diabetes medications is expected to be over $40 Billion USD by 2020.

The global skin lightening market is expected to reach $20 Billion USD by 2020.

Next Generation Anti-aging Patent

Sirona also announces that its early stage patent application for the second generation of glycoprotein compounds (included its anti-aging and regenerative medicine compound SBM-TFC-837) obtained a favorable international search report and written opinion from the international searching authority. A favorable search indicates that there were no similar inventions, which would block the patent from being granted. These compounds have a wide range of potential commercial applications.

The global anti-aging market is expected to reach $345.8 billion US in 2018.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

  • For more information regarding this press release, please contact:
    Christopher Hopton
    CFO
    Sirona Biochem Corp.
    Phone: 1.604.282.6064
    Email: chopton@sironabiochem.com